Case report {#sec0005}
===========

A 30-year-old Aboriginal man from central Australia who was infected with the Human T-cell leukemia virus type 1 (HTLV-1) and presented to Alice Springs Hospital with severe acute dyspnea, productive cough and fever. On examination he was febrile (38.2 °C), dyspneic, with tachypnea (respiratory rate, 32 breaths per minute) and hypoxia (oxygen saturation, 42 % on room air). Fingers and toes were clubbed and chest auscultation revealed widespread expiratory wheezes with bibasal coarse crackles. Cardiovascular examination revealed an elevated jugular venous pressure, a loud P2 and peripheral edema. Initial investigations showed that he had hypercapnic respiratory failure with arterial blood gas showing a pO2 of 49.8 mm Hg and pCO2 of 80 mm Hg. Chest high resolution computed tomography (cHRCT) showed centrilobular nodules, patchy ground glass opacity, thickening of bronchovascular bundles and mild bibasal bronchiectasis ([Fig. 1](#fig0005){ref-type="fig"}). He was admitted to the intensive care unit and treated with non-invasive bi-level positive airway pressure ventilation. Empirical antibacterial for chest infection and high dose corticosteroids (intravenous hydrocortisone 100 mg every 6 hourly) were commenced. However, he did not improve and required invasive ventilation. While intubated, bronchoscopy was performed and bronchoalveolar lavage fluid (BALF) obtained for analysis. This revealed a predominant lymphocytic infiltration (total leukocytes, 4.05 × 10^5^/ml; lymphocytes, 95 %; neutrophils, 5%), and a diagnosis of lymphocytic bronchiolitis was therefore made.Fig. 1A, B, C: CT chest showing centrilobular nodules, patchy ground glass opacity, thickening of bronchovascular bundles and bibasal bronchiectasis. D: Bilateral pulmonary micronodules.Fig. 1

The patient first developed respiratory problems approximately 2 years prior to this presentation. He played competitive Australian Rules football prior to his respiratory symptoms onset. In the previous 2 years, he was hospitalised 4 times with severe acute dyspnea and hypercapnic respiratory failure. On each occasion, he promptly responded to high dose corticosteroids, but was not adherent to corticosteroid therapy as an out-patient.

A final diagnosis of HTLV-1c associated bronchiolitis (HAB) was made on the basis of positive HTLV-1 serology, with a confirmatory HTLV-1 western blot and high HTLV-1 proviral loads (PVL) in peripheral blood (6.8 HTLV-1 DNA copies per 100 peripheral blood leukocytes) and BALF (4.7 HTLV-1 DNA copies per 100 BALF lymphocyte). The HTLV-1 virus in blood and BALF was HTLV-1 subtype C which is endemic to the Indigenous population of central Australia. Extensive investigations excluded other causes of bronchiolitis/bronchiectasis and cardiac investigations failed to find a cardiovascular cause for his right heart failure ([Table 1](#tbl0005){ref-type="table"}). These findings were consistent with HTLV-1 associated pneumopathy, manifesting as a multi-lobar bronchiolitis and bi-babasal tubular bronchiectasis, complicated by cor pulmonale.Table 1Other investigation findings.Table 1Pulmonary function testsSevere obstructive ventilator defect not significantly improved with bronchodilator therapy. Reduce DLco(33 mmol/kPa/min) and increased residual volume(1.8 L). Marked oxygen desaturation at 88 % on room air.ElectrocardiographySinus rhythm, P pulmonaleTransthoracic echocardiogramEjection fraction 46 %. Dilated right ventricle with reduced function. Mild right ventricular hypertrophy.Cardiac magnetic resonance imagingSevere right ventricular systolic dysfunctionCoronary angiographyMinimal coronary artery disease. Less than 20 % circumflex disease. Mild pulmonary hypertension, mean pulmonary artery pressure 24 mm Hg, wedge pressure 7 mm Hg.Alpha 1 antitrypisin1.51 g/L (normal)Human immunodeficiency virusNegativeBlood cultures (3 sets)No growthPan-respiratory viruses PCR on BALFNo virus detectedBALF mycobacteria culturesNo growthBALF fungal culturesNo growthBALF bacterial culturesHaemophilus influenzaAspergillus IgE precipitinsNot detectedImmunoglobulinsTotal IgG 17.1 g/L (6.50--17.0)IgG1 15.55 g/L (3.40--9.20)IgG2 1.71 g/L (1.40--7.50)IgG3 0.95 g/L (0.20--1.20)IgG4 0.19 g/L (\< 1.50)

The patient responded well to treatment with intravenous hydrocortisone 100 mg every 6 hourly. He was extubated after 4 days of assisted ventilation, at which time intravenous hydrocortisone was ceased and oral prednisolone 50 mg daily commenced. Unfortunately, he did not attend outpatient follow-up and died in his community 8 months later after again developing respiratory distress and not seeking medical assistance.

Discussion {#sec0010}
==========

HTLV-1 is an oncogenic human retrovirus that preferentially infects CD4 + T cells \[[@bib0005]\]. HTLV-1 infects up to 20 million people worldwide who predominantly dwell in areas of high endemicity in south-western Japan and developing countries of the Carribean basin, South America, and sub-Saharan Africa \[[@bib0010]\]. An endemic focus is also present in central Australia where infection with the Australo-Melanesian HTLV-1 subtype C is prevalent \[[@bib0015]\].

Central Australia is a sparsely populated region covering 830,000 km^2^. Approximately 40 % of the population are Aboriginal Australians, the majority of which live in isolated remote communities \[[@bib0065]\]. HTLV-1 is endemic in central Australia and has the highest recorded regional prevalence of HTLV-1 infection worldwide; more than 40 % of adults are infected with HTLV-1 subtype C \[[@bib0015]\] in some remote Indigenous communities \[[@bib0020]\]. HTLV-1 is the recognised cause of Adult T cell leukemia-lymphoma (ATL) and HTLV-1 associated myelopathy (HAM) \[[@bib0005]\]. It is also associate with a range of inflammatory diseases involving the lungs, eye and skin \[[@bib0025]\]. Risk of complications of HTLV-1 is strongly associated with a higher HTLV-1 PVL \[[@bib0005]\].

HTLV-1 associated pulmonary diseases include a range of disease entities including alveolitis, bronchiolitis, bronchitis and bronchiectasis \[[@bib0030]\]. Pathological studies from lung biopsy and autopsy specimens reveal infiltration of small airways by lymphocytes and high numbers of infected lymphocytes have been recovered in BALF \[[@bib0030],[@bib0035]\]. Similar to other HTLV-1 associated inflammatory diseases, HTLV-1 associated bronchiolitis (HAB) is thought to be caused by inflammation mediated by HTLV-1-infected CD4^+^ T cells. Inefficient cytotoxic T lymphocyte response in host leads to pervasive dissemination of HTLV-1 virus in substantial quantity of HTLV-1-infected T-lymphocytes clones, which is reflected in high HTLV-1 PVL \[[@bib0040]\]. HTLV-1 infected Treg cells produce interferon gamma, which is thought to establish a positive inflammatory feedback loop in affected tissues \[[@bib0045]\]. This is consistent previous reports that a higher HTLV-1 PVL is associated with more extensive radiologically defined pulmonary injury \[[@bib0050]\]. The HTLV-1 PVL in our patient was very high (6.8 %) and this was associated with extensive bronchiolitis, which may be the precursor to mild bronchiectasis in this case \[[@bib0040]\]. A high HTLV-1 PVL predicts death due to bronchiectasis in this population \[[@bib0040],[@bib0050]\]. Infection with HTLV-1c significantly increases the risk of bronchiolitis in central Australia \[[@bib0040]\]; however, this is the first description of the clinical presentation of this condition.

There are currently no guidelines to direct the management of HTLV-1 associated lung diseases. As demonstrated in this case report, HAB responds rapidly to treatment with corticosteroids, which suppress the pro-inflammatory cytokines and chemokines produced by the infected T cells. However, steroid related complications have encouraged the addition of corticosteroids sparing agent in the longer term such as cyclosporine, azathioprine, salazopyrine and methotrexate \[[@bib0070]\]. Most recently, a Japanese group has demonstrated the efficacy of mogamulizumab (anti-CCR4) as a means to reduce the HTLV-1 PVL and the inflammatory response associated with a high HTLV-1 PVL \[[@bib0055]\]. Unfortunately, there are no effective antiretroviral agents for HTLV-1 infection which replicates by clonal proliferation in chronic infections \[[@bib0060],[@bib0070]\].

In conclusion, this is the first clinical description of HAB resulting from infection with HTLV-1 subtype C. Clinicians should consider HTLV-1 associated pulmonary disease as a potential cause of bronchiolitis in patients with HTLV-1 as treatment with corticosteroids can be lifesaving. There is also a need to better understand the pathogenesis of this condition in order to develop better targeted therapies.
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